Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.

Plasma-based tumor mutational profiling is arising as a reliable approach to detect primary and therapy-induced resistance mutations required for accurate treatment decision making. Here, we compared the FDA-approved Cobas EGFR Mutation Test v2 with the UltraSEEK™ Lung Panel on the MassARRAY System on detection of mutations, accompanied with preanalytical sample assessment using the novel Liquid IQ Panel. 137 cancer patient-derived cell-free plasma samples were analyzed with the Cobas and UltraSEEK™ tests.